{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:00:54Z","timestamp":1780984854628,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","award":["VEO-000961"],"award-info":[{"award-number":["VEO-000961"]}],"id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40121-026-01322-7","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:02:15Z","timestamp":1775638935000},"page":"1509-1524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modeling the Public Health Impact of Introducing 4CMenB Vaccination for Infants in the Brazilian National Immunization Program"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0957-3118","authenticated-orcid":false,"given":"Thatiana","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5231-3389","authenticated-orcid":false,"given":"Zeki","family":"Kocaata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8216-2350","authenticated-orcid":false,"given":"Ana","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1557-7062","authenticated-orcid":false,"given":"Igor","family":"Sampietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-4648","authenticated-orcid":false,"given":"Graziela","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9759-1960","authenticated-orcid":false,"given":"Justyna","family":"Zawieja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9908-4878","authenticated-orcid":false,"given":"Yaneth","family":"Gil-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8827-1469","authenticated-orcid":false,"given":"Anna","family":"Tytu\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9577-4428","authenticated-orcid":false,"given":"Maria Gabriela","family":"Gra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3528-5507","authenticated-orcid":false,"given":"Elise","family":"Kuylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"5","key":"1322_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1086\/511646","volume":"44","author":"P Boisier","year":"2007","unstructured":"Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44(5):657\u201363. https:\/\/doi.org\/10.1086\/511646.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1322_CR2","first-page":"006","volume":"1","author":"J Leimkugel","year":"2009","unstructured":"Leimkugel J, Racloz V, da Jacintho Silva L, Pluschke G. Global review of meningococcal disease. A shifting etiology. J Bacteriol Res. 2009;1(1):006\u201318.","journal-title":"J Bacteriol Res"},{"issue":"5","key":"1322_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/s1473-3099(10)70048-7","volume":"10","author":"K Edmond","year":"2010","unstructured":"Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317\u201328. https:\/\/doi.org\/10.1016\/s1473-3099(10)70048-7.","journal-title":"Lancet Infect Dis"},{"key":"1322_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012393","author":"M Coureuil","year":"2013","unstructured":"Coureuil M, Join-Lambert O, L\u00e9cuyer H, Bourdoulous S, Marullo S, Nassif X. Pathogenesis of meningococcemia. Cold Spring Harb Perspect Med. 2013. https:\/\/doi.org\/10.1101\/cshperspect.a012393.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"1322_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/bmb\/ldh041","volume":"72","author":"S Segal","year":"2005","unstructured":"Segal S, Pollard AJ. Vaccines against bacterial meningitis. Br Med Bull. 2005;72(1):65\u201381. https:\/\/doi.org\/10.1093\/bmb\/ldh041.","journal-title":"Br Med Bull"},{"issue":"1","key":"1322_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-12933-3","volume":"22","author":"S Guedes","year":"2022","unstructured":"Guedes S, Bricout H, Langevin E, Tong S, Bertrand-Gerentes I. Epidemiology of invasive meningococcal disease and sequelae in the United Kingdom during the period\u00a02008 to 2017 - a secondary database analysis. BMC Public Health. 2022;22(1):521. https:\/\/doi.org\/10.1186\/s12889-022-12933-3.","journal-title":"BMC Public Health"},{"issue":"1","key":"1322_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.14295\/vittalle.v32i1.9645","volume":"32","author":"MM Silveira","year":"2020","unstructured":"Silveira MM, McBride A, Trotter C. Invasive meningococcal disease in Brazil: a literature review. VITTALLE - Revista de Ci\u00eancias da Sa\u00fade. 2020;32(1):165\u201373. https:\/\/doi.org\/10.14295\/vittalle.v32i1.9645.","journal-title":"VITTALLE - Revista de Ci\u00eancias da Sa\u00fade"},{"key":"1322_CR8","doi-asserted-by":"publisher","unstructured":"Chicuto LAD, Camile dM, Jos\u00e9 CdM, S\u00e1fadi MAP. A critical analysis of serogroup b meningococcal disease burden in Brazil (2001\u20132015): implications for public health decisions. Hum Vacc Immunotherap. 2020;16(8):1945\u201350. https:\/\/doi.org\/10.1080\/21645515.2019.1700710.","DOI":"10.1080\/21645515.2019.1700710"},{"key":"1322_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijid.2019.01.009","volume":"80","author":"JV Presa","year":"2019","unstructured":"Presa JV, de Almeida RS, Spinardi JR, Cane A. Epidemiological burden of meningococcal disease in Brazil: a systematic literature review and database analysis. Int J Infect Dis. 2019;80:137\u201346. https:\/\/doi.org\/10.1016\/j.ijid.2019.01.009.","journal-title":"Int J Infect Dis"},{"key":"1322_CR10","unstructured":"National Information System for Notifiable Diseases. Brazilian health information system. http:\/\/siab.datasus.gov.br\/DATASUS\/index.php?area=060805. Accessed June 13, 2025."},{"key":"1322_CR11","unstructured":"Minist\u00e9rio da Sa\u00fade. Informe meningites. https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/saude-de-a-a-z\/m\/meningite\/situacao-epidemiologica\/dados-epidemiologicos\/informe-meningite.pdf\/view. Accessed July 25, 2025."},{"issue":"2","key":"1322_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","volume":"116","author":"F Martin\u00f3n-Torres","year":"2022","unstructured":"Martin\u00f3n-Torres F, Muhamed-Kheir T, Markus K, et al. Evolving strategies for meningococcal vaccination in europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2022;116(2):85\u201398. https:\/\/doi.org\/10.1080\/20477724.2021.1972663.","journal-title":"Pathog Glob Health"},{"issue":"9","key":"1322_CR13","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1586\/erv.11.103","volume":"10","author":"D Panatto","year":"2011","unstructured":"Panatto D, Daniela A, Luigi LP, Gasparini R. Neisseria meningitidis B vaccines. Expert Rev Vaccines. 2011;10(9):1337\u201351. https:\/\/doi.org\/10.1586\/erv.11.103.","journal-title":"Expert Rev Vaccines"},{"key":"1322_CR14","doi-asserted-by":"publisher","unstructured":"Aparecido Nunes A, De Jesus Lopes De Abreu A, Cintra O, et al. Meningococcal disease epidemiology in Brazil (2005\u20132018) and impact of MenC vaccination. Vaccine. 2021;39(3):605\u201316. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.067.","DOI":"10.1016\/j.vaccine.2020.11.067"},{"issue":"12","key":"1322_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11121841","volume":"11","author":"R Villena","year":"2023","unstructured":"Villena R, Safadi MA, Gentile \u00c1, et al. Epidemiology of meningococcal disease in four South American countries and rationale of vaccination in adolescents from the region: position paper of the Latin American Society of Pediatric Infectious Diseases (SLIPE). Vaccines. 2023;11(12):1841.","journal-title":"Vaccines"},{"key":"1322_CR16","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa). Consultas. https:\/\/consultas.anvisa.gov.br\/#\/bulario\/q\/?numeroRegistro=101070321. Accessed June 6, 2025."},{"key":"1322_CR17","doi-asserted-by":"publisher","unstructured":"Mbaeyi S, Bozio C, Duffy J, et al. Meningococcal vaccination: Recommendations of the advisory committee on immunization practices, United States, 2020. Recomm Rep. 2020;RR9:1\u201341. https:\/\/doi.org\/10.15585\/mmwr.rr6909a1.","DOI":"10.15585\/mmwr.rr6909a1"},{"key":"1322_CR18","unstructured":"Rubis A. Epidemiology of meningococcal disease in the United States. 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/02-Mening-Rubis-508.pdf. Accessed Aug 19, 2025"},{"key":"1322_CR19","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica. Population estimates. https:\/\/www.ibge.gov.br\/en\/statistics\/social\/population\/18176-population-projection.html. Accessed June 13, 2025."},{"key":"1322_CR20","unstructured":"Institute for Health Metrics and Evaluation (IHME). Gbd compare. http:\/\/vizhub.healthdata.org\/gbd-compare. Accessed June 13, 2025."},{"issue":"7","key":"1322_CR21","doi-asserted-by":"publisher","first-page":"e1661","DOI":"10.1093\/cid\/ciaa1244","volume":"73","author":"SN Ladhani","year":"2021","unstructured":"Ladhani SN, Campbell H, Andrews N, et al. First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: prospective enhanced national surveillance, England. Clin Infect Dis. 2021;73(7):e1661\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaa1244.","journal-title":"Clin Infect Dis"},{"key":"1322_CR22","unstructured":"Minist\u00e9rio da Sa\u00fade. Comiss\u00e3o nacional de incorpora\u00e7\u00e3o de tecnologias no sistema \u00fanico de sa\u00fade (conitec). https:\/\/www.gov.br\/conitec\/pt-br\/midias\/artigos_publicacoes\/diretrizes\/diretriz-de-avaliacao-economica.pdf\/view. Accessed October 8, 2025."},{"issue":"1","key":"1322_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06906-x","volume":"21","author":"L Argante","year":"2021","unstructured":"Argante L, Abbing-Karahagopian V, Vadivelu K, Rappuoli R, Medini D. A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model. BMC Infect Dis. 2021;21(1):1244. https:\/\/doi.org\/10.1186\/s12879-021-06906-x.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1322_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jinf.2023.05.021","volume":"87","author":"B Wang","year":"2023","unstructured":"Wang B, Giles L, Andraweera P, et al. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation. J Infect. 2023;87(2):95\u2013102. https:\/\/doi.org\/10.1016\/j.jinf.2023.05.021.","journal-title":"J Infect"},{"issue":"7","key":"1322_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/s1473-3099(21)00754-4","volume":"22","author":"B Wang","year":"2022","unstructured":"Wang B, Giles L, Andraweera P, et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup V meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect Dis. 2022;22(7):1011\u201320. https:\/\/doi.org\/10.1016\/s1473-3099(21)00754-4.","journal-title":"Lancet Infect Dis"},{"key":"1322_CR26","unstructured":"Minist\u00e9rio da Sa\u00fade. Datasus. http:\/\/tabnet.datasus.gov.br\/cgi\/dhdat.exe?bd_pni\/cpnibr.def. Accessed June 13, 2025."},{"issue":"1","key":"1322_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228020","volume":"15","author":"L Huang","year":"2020","unstructured":"Huang L, Heuer OD, Jan\u00dfen S, H\u00e4ckl D, Schmedt N. Clinical and economic burden of invasive meningococcal disease: evidence from a large German claims database. PLoS One. 2020;15(1):e0228020. https:\/\/doi.org\/10.1371\/journal.pone.0228020.","journal-title":"PLoS One"},{"key":"1322_CR28","volume-title":"An\u00e1lise e determina\u00e7\u00e3o de custos espec\u00edficos e consequ\u00eancias econ\u00f4mico-sociais na incorpora\u00e7\u00e3o da vacina contra meningite e doen\u00e7a meningoc\u00f3cica c conjugada na rotina do programa nacional de imuniza\u00e7\u00e3o\/pni (2011)","author":"A Itria","year":"2011","unstructured":"Itria A. An\u00e1lise e determina\u00e7\u00e3o de custos espec\u00edficos e consequ\u00eancias econ\u00f4mico-sociais na incorpora\u00e7\u00e3o da vacina contra meningite e doen\u00e7a meningoc\u00f3cica c conjugada na rotina do programa nacional de imuniza\u00e7\u00e3o\/pni (2011). Doutorado. S\u00e3o Paulo: Universidade de S\u00e3o Paulo; 2011."},{"issue":"23","key":"1322_CR29","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","volume":"31","author":"H Christensen","year":"2013","unstructured":"Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup\u00a0B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31(23):2638\u201346. https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.034.","journal-title":"Vaccine"},{"key":"1322_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5725","volume":"349","author":"H Christensen","year":"2014","unstructured":"Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725. https:\/\/doi.org\/10.1136\/bmj.g5725.","journal-title":"BMJ"},{"issue":"29","key":"1322_CR31","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","volume":"34","author":"H Christensen","year":"2016","unstructured":"Christensen H, Irving T, Koch J, et al. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero\u00ae to reduce meningococcal group\u00a0B disease in Germany. Vaccine. 2016;34(29):3412\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.004.","journal-title":"Vaccine"},{"issue":"5","key":"1322_CR32","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.4161\/hv.23888","volume":"9","author":"KB Pouwels","year":"2013","unstructured":"Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GPJM, Postma MJ. Cost-effectiveness of vaccination against meningococcal B among Dutch infants. Hum Vaccin Immunother. 2013;9(5):1129\u201338. https:\/\/doi.org\/10.4161\/hv.23888.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"1322_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.vaccine.2016.11.076","volume":"35","author":"H Christensen","year":"2017","unstructured":"Christensen H, Trotter CL. Modelling the cost-effectiveness of catch-up \u2018MenB\u2019 (Bexsero) vaccination in England. Vaccine. 2017;35(2):208\u201311. https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.076.","journal-title":"Vaccine"},{"issue":"5","key":"1322_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177082","volume":"12","author":"ITR Kennedy","year":"2017","unstructured":"Kennedy ITR, van Hoek AJ, Ribeiro S, et al. Short-term changes in the health state of children with group B meningococcal disease: a prospective, national cohort study. PLoS One. 2017;12(5):e0177082. https:\/\/doi.org\/10.1371\/journal.pone.0177082.","journal-title":"PLoS One"},{"issue":"5","key":"1322_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/322587","volume":"33","author":"LJ Erickson","year":"2001","unstructured":"Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737\u20139. https:\/\/doi.org\/10.1086\/322587.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1322_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/bjo.85.3.327","volume":"85","author":"MM Brown","year":"2001","unstructured":"Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85(3):327\u201331. https:\/\/doi.org\/10.1136\/bjo.85.3.327.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1322_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s0895-4356(02)00448-1","volume":"55","author":"R Oostenbrink","year":"2002","unstructured":"Oostenbrink R, Ha AM, Essink-Bot ML. The EQ-5D and the health utilities index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791\u20139. https:\/\/doi.org\/10.1016\/s0895-4356(02)00448-1.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"1322_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001307","volume":"9","author":"M Wyld","year":"2012","unstructured":"Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9):e1001307. https:\/\/doi.org\/10.1371\/journal.pmed.1001307.","journal-title":"PLoS Med"},{"issue":"12","key":"1322_CR39","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/hec.3259","volume":"25","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi H, Van Exel J, Brouwer W, et al. Measuring health spillovers for economic evaluation: a case study in meningitis. Health Econ. 2016;25(12):1529\u201344. https:\/\/doi.org\/10.1002\/hec.3259.","journal-title":"Health Econ"},{"key":"1322_CR40","doi-asserted-by":"publisher","unstructured":"Blakeney P, Meyer W, 3rd, Robert R, Desai M, Wolf S, Herndon D. Long-term psychosocial adaptation of children who survive burns involving 80% or greater total body surface area. J Trauma. 1998;44(4):625\u201332; discussion 33\u20134. https:\/\/doi.org\/10.1097\/00005373-199804000-00011.","DOI":"10.1097\/00005373-199804000-00011"},{"issue":"4","key":"1322_CR41","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1192\/bjp.bp.106.025106","volume":"190","author":"SI Saarni","year":"2007","unstructured":"Saarni SI, Suvisaari J, Sintonen H, et al. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry. 2007;190(4):326\u201332. https:\/\/doi.org\/10.1192\/bjp.bp.106.025106.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"1322_CR42","first-page":"43","volume":"154","author":"JE Bennett","year":"2000","unstructured":"Bennett JE, Sumner W, Downs SM, Jaffe DM. Parents\u2019 utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154(1):43\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"1322_CR43","unstructured":"CONITEC. Health economic guidelines for Brazil. https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/diretrizes_metodologicas_diretriz_avaliacao_economica.pdf. Accessed June 13, 2025."},{"issue":"7","key":"1322_CR44","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.vaccine.2015.11.057","volume":"34","author":"PS Watson","year":"2016","unstructured":"Watson PS, Turner DP. Clinical experience with the meningococcal B vaccine, Bexsero(\u00ae): prospects for reducing the burden of meningococcal serogroup B disease. Vaccine. 2016;34(7):875\u201380. https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.057.","journal-title":"Vaccine"},{"key":"1322_CR45","unstructured":"CFR-PR. Anvisa autoriza registro de vacina contra meningite b. https:\/\/www.crf-pr.org.br\/noticia\/view\/5522. Accessed 26-Jan."},{"key":"1322_CR46","unstructured":"Ministerio de Salud (MINSAL). Vacunas del programa nacional de inmunizaciones del minsal. https:\/\/www.chileatiende.gob.cl\/fichas\/105622-vacunas-del-programa-nacional-de-inmunizaciones-del-minsal? Accessed Aug 11, 2025."},{"key":"1322_CR47","unstructured":"Ministerio de Salud (MINSAL). https:\/\/saludresponde.minsal.cl\/preguntas-frecuentes-vacuna-contra-el-meningococo-b\/. Accessed"},{"key":"1322_CR48","unstructured":"Minist\u00e9rio da Sa\u00fade. Vacunas. https:\/\/vacunas.minsal.cl\/cavei\/recomendaciones-cavei\/. Accessed July 24."},{"key":"1322_CR49","unstructured":"Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes, 4th edition. Oxford University Press; 2015."},{"issue":"4","key":"1322_CR50","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","volume":"16","author":"R Borrow","year":"2017","unstructured":"Borrow R, Alarc\u00f3n P, Carlos J, et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313\u201328. https:\/\/doi.org\/10.1080\/14760584.2017.1258308.","journal-title":"Expert Rev Vaccines"},{"key":"1322_CR51","unstructured":"World Health Organization (WHO). Meningitis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningitis. Accessed June 5, 2025."},{"issue":"9960","key":"1322_CR52","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/s0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase\u00a03 randomised clinical trial. Lancet. 2014;384(9960):2123\u201331. https:\/\/doi.org\/10.1016\/s0140-6736(14)60842-4.","journal-title":"Lancet"},{"issue":"1","key":"1322_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00388-3","volume":"6","author":"Y Ruiz Garc\u00eda","year":"2021","unstructured":"Ruiz Garc\u00eda Y, Sohn WY, Seib KL, et al. Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect. NPJ Vaccines. 2021;6(1):130. https:\/\/doi.org\/10.1038\/s41541-021-00388-3.","journal-title":"NPJ Vaccines"},{"issue":"47","key":"1322_CR54","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.1016\/j.vaccine.2020.09.050","volume":"38","author":"A Biolchi","year":"2020","unstructured":"Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.050.","journal-title":"Vaccine"},{"key":"1322_CR55","doi-asserted-by":"publisher","unstructured":"Lecocq H, Parent du Ch\u00e2telet I, Taha MK, L\u00e9vy-Bruhl D, Dervaux B. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34(19):2240\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.020.","DOI":"10.1016\/j.vaccine.2016.03.020"}],"updated-by":[{"DOI":"10.1007\/s40121-026-01368-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01322-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:34:11Z","timestamp":1780983251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01322-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01322-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The copyright holder for this article was incorrectly given as 'The Author(s)' but should have been 'GSK Plc.'.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-026-01368-7","URL":"https:\/\/doi.org\/10.1007\/s40121-026-01368-7","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thatiana Pinto, Elise Kuylen, Ana Medina, Igor Sampietri, Graziela Bernardino, Maria Gabriela Gra\u00f1a and Zeki Kocaata are employed by and hold financial equities in GSK. Justyna Zawieja, Yaneth Gil-Rojas and Anna Tytu\u0142a are employees of Putnam, who received funding from GSK for this study. The authors disclose no other financial and non-financial relationships and activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}